$355 Million is the total value of CHI Advisors LLC's 23 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RPTX | Buy | REPARE THERAPEUTICS INC | $86,853,000 | +11.5% | 2,532,150 | +0.1% | 24.47% | -11.7% |
| ONCR | New | ONCORUS INC | $54,312,000 | – | 1,679,906 | +100.0% | 15.30% | – |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $53,501,000 | +0.4% | 2,354,799 | +0.1% | 15.07% | -20.5% |
| FRLN | Buy | FREELINE THERAPEUTICS HLDGSsponsored ads | $24,853,000 | +20.2% | 1,361,064 | +2.8% | 7.00% | -4.8% |
| AKUS | Buy | AKOUOS INC | $17,270,000 | -10.8% | 870,897 | +2.9% | 4.86% | -29.3% |
| OVID | Buy | OVID THERAPEUTICS INC | $1,911,000 | -46.1% | 827,260 | +33.8% | 0.54% | -57.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $987,000 | +11.9% | 22,800 | +42.5% | 0.28% | -11.5% |
| XBI | New | SPDR SER TRput | $54,000 | – | 10,000 | +100.0% | 0.02% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INcall | $8,000 | -69.2% | 20,000 | +100.0% | 0.00% | -77.8% |
| DTIL | New | PRECISION BIOSCIENCES INCcall | $8,000 | – | 10,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.